UTime has commenced a comprehensive financial and legal due diligence on Bowen Therapeutics, which it intends to acquire. Bowen Therapeutics is expected to become a key part of UTime’s expansion strategy. Bowen Therapeutics’ progress in the development of monkeypox vaccine has contributed a number of breakthrough technologies to global healthcare. UTime intends to leverage the proposed acquisition to integrate Bowen Therapeutics’s advanced technologies and research and development capabilities in order to facilitate the company’s technological innovation and market expansion in the healthcare sector.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WTO: